Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the combination of the anti-cancer drugs
durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and
neck cancer. Participants will receive both durvalumab and cetuximab.